Ograniczanie wyników

Czasopisma help

  1. 6 Journal of Physiology and Pharmacology

  2. 4 Archivum Immunologiae et Therapiae Experimentalis

  3. 4 Folia Histochemica et Cytobiologica

  4. 2 International Letters of Natural Sciences

  5. 1 Acta Biochimica Polonica

Więcej...
Autorzy help

  1. 4 Lekstan A.

  2. 3 Dranka-Bojarowska D.

  3. 3 Lampe P.

  4. 2 Duda-Barcik L.

  5. 2 Grzebieniak Z.

Więcej...
Lata help

  1. 1 2021

  2. 1 2020

  3. 1 2019

  4. 2 2016

  5. 3 2015

Więcej...
Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 18

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  pancreatic cancer
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1

Signal transduction in human pancreatic cancer: roles of transforming growth factor beta, somatostatin receptors, and other signal intermediates

100%
Li M., Becnel L. S., Li W., Fisher W. E., Chen C., Yao Q.
Archivum Immunologiae et Therapiae Experimentalis
|
2005
|
tom 53
|
nr 5
2
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Mini-review on the glucose metabolism modifications after pancreatic resection

86%
Timofte D., Ionescu L., Ochiuz L.
International Letters of Natural Sciences
|
2016
|
tom 53
Pancreatic cancer is one of the most severe malignant disease, with an extreme degree of lethality, considering that the survival rate at 5 years is up to 4%. In addition, a major disadvantage of this disease is the fact that the diagnosis is determined very late in the evolution of the disorder, despite the development of new technologies. In this way, the main symptoms are occurring later on, when the tumour is well to advanced and totally unresectable. Up to now surgery is the only modality that can provide a greater chance of survival, but unfortunately the pancreatic resection has many unknowns and controversies around it. Moreover, the studies on endocrine pancreatic function after resection are very few and somehow controversial. In this way, in the present minireview we will describe the most relevant experimental data regarding the post-resection pancreatogenic diabetes, the pancreatic polypeptide PP and the pancreatic glucose metabolism after resection or the glucose metabolism after partial or total pancreatectomy.
3
Content available remote

Transcriptional upregulation of gastrin in response to peroxisome proliferator-activated receptor gamma agonist triggers cell survival pathways

86%
Ptak-Belowska A., Pawlik M. W., Krzysiek-Maczka G., Brzozowski T., Pawlik W. W.
Journal of Physiology and Pharmacology
|
2007
|
tom 58
|
nr 4
Peroxisome proliferator-activated receptor (PPAR ) are members of the largest nuclear hormone receptor family of transcription factors (1). PPAR gamma (PPAR) plays an important role in adipogenesis, control of sensitivity to insulin, inflammation and atherosclerosis but recent studies also suggest that PPAR is involved in cell cycle withdrawal. PPAR can promote cell differentiation, exert an antiproliferative action and inhibit angiogenesis (2, 3). However, there are studies showing that activation of PPAR promotes the development of colon cancer (4). These data are in sharp contrast with studies that attribute anticancer effects to PPAR in gastrointestinal malignancies. Probably, the action of PPAR on cell cycle and proliferation depends on the cell type and presence of other stimuli that predispose cells to cancer development. Amidated and non-amidated gastrins may play an important role in the proliferation and carcinogenesis of GI cancers. It is known that gastrin peptides activate phosphorylation of Protein Kinase B (PKB/Akt) and anti-apoptotic signalling but there is little known about the link between gastrins and PPAR receptors in relation to apoptosis.
4

The Q705K and F359L single-nucleotide polymorphisms of NOD-like receptor signaling pathway: association with chronic pancreatitis, pancreatic cancer, and periodontitis

72%
Miskiewicz A., Szparecki G., Durlik M., Rydzewska G., Ziobrowski I., Gorska R.
Archivum Immunologiae et Therapiae Experimentalis
|
2015
|
tom 63
|
nr 6
5
Content available remote

The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis

72%
Dranka-Bojarowska D., Lewinski A., Lekstan A., Gajda M., Ciosek J., Mrowiec S.
Journal of Physiology and Pharmacology
|
2020
|
tom 71
|
nr 5
6
Content available remote

The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis

72%
Dranka-Bojarowska D., Lekstan A., Olakowski M., Jablonska B., Lewinski A., Musialski P., Sobczyk W., Kapalka A., Lampe P.
Journal of Physiology and Pharmacology
|
2015
|
tom 66
|
nr 5
7
Content available remote

The role of the tissue plasminogen activator as a prognostic and differentiation factor in patients with pancreatic cancer and chronic pancreatitis

72%
Baluka D., Urbanek T., Lekstan A., Swietochowska E., Wiaderkiewicz R., Kajor M., Jedrzejewska-Szypulka H., Kusnierz K., Lampe P.
Journal of Physiology and Pharmacology
|
2016
|
tom 67
|
nr 1
8
Content available remote

Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin

72%
Budzynska A., Nowakowska-Dulawa E., Marek T., Boldys H., Nowak A., Hartleb M.
Journal of Physiology and Pharmacology
|
2013
|
tom 64
|
nr 1
9

Prognostic value of CA 19-9 level in resectable pancreatic adenocarcinoma

72%
Rudnicki J., Agrawal A. K., Grzebieniak Z., Zukrowski P., Zysko D., Jelen M., Kielan W., Sebastian M., Slonina J., Marek G., Duda-Barcik L.
Folia Histochemica et Cytobiologica
|
2010
|
tom 48
|
nr 2
249-261
10

Leukemia inhibitory factor: a potential biomarker and therapeutic target in pancreatic cancer

72%
Wrona E., Potemski P., Sclafani F., Borowiec M.
Archivum Immunologiae et Therapiae Experimentalis
|
2021
|
tom 69
|
nr 1
11

Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer

72%
Gunzburg W. H., Salmons B.
Acta Biochimica Polonica
|
2005
|
tom 52
|
nr 3
Although approved for the treatment of pancreatic cancer, the chemotherapeutic agent ifosfamide is not an effective therapy for this type of tumour. Ifosfamide must be activated by cytochrome P450 (P450) enzymes in the liver, initially to a short lived intermediate and then to toxic metabolites that are subsequently distributed by the circulatory system. Particularly for pancreatic cancer, this liver-mediated conversion results in relatively high systemic toxicities and poor therapeutic concentrations at the liver-distant site of the tumour. Activation of ifosfamide at the site of the tumour may allow lower doses to be used, while increasing the therapeutic index due to the resultant active concentrations generated locally. A cell-based therapy has been conceived where encapsulated, 293-derived cells genetically modified to overexpress a cytochrome P450 enzyme, are implanted near solid tumours. The cells are encapsulated in polymers of cellulose sulphate in order to provide a means of immunoprotection in vivo as well as to physically constrain them to the vicinity of the tumour. A major advantage of this strategy is that it allows one standard cell line to be applied to all patients and this approach can be extended to the treatment of other tumour types. After proof of principle studies in animal models, a phase I/II clinical trial was initiated in patients with stage III/IV nonresectable pancreatic cancer. Encapsulated cells were angiographically placed into the tumour vasculature of 14 patients and followed by systemic low dose ifosfamide treatment. Angiographic delivery of encapsulated cells proved feasible in all but one patient, and was well tolerated with no capsule or ifosfamide treatment-related adverse events. Four of the treated patients showed tumour regressions after capsule delivery and ifosfamide treatment in computer-tomography scans. The other 10 patients showed no further tumour growth (i.e. stable disease) during 20 weeks observation period. The median life expectancy of the patient collective was extended two fold as compared to age and status matched historical controls, with a 3-fold improvement in one year survival being attained. Evidence for a clinical benefit of the treatment was also obtained on the basis of standard parameters for quality of life. This approach has been evaluated by the European Medicines Evaluation Agency (EMEA) and orphan drug status has been granted. A pivotal clinical trial is now being planned with the help of the EMEA. Taken together, the data from this clinical trial suggest that encapsulated cytochrome P450-expressing cells combined with chemotherapy may be useful for the local treatment of a number of solid tumours and support the performance of further clinical studies of this new treatment.
12

Microvascular density in chronic pancreatitis and pancreatic ductal adenocarcinoma

72%
Rzepko R., Jaskiewicz K., Klimkowska M., Nalecz A., Izycka-Swieszewska E.
Folia Histochemica et Cytobiologica
|
2003
|
tom 41
|
nr 4
13

Inhibition of cysteine peptidase activity in ascitic fluid in pancreatic cancer patients

58%
Agrawal A., Kielan W., Katib A., Grzebieniak Z., Skalski A., Grzebieniak T., Duda-Barcik L., Janocha A., Siewinski M.
Folia Histochemica et Cytobiologica
|
2010
|
tom 48
|
nr 4
14
Content available remote

Concentrations and activities of metalloproteinases 2 and 9 and their inhibitors (TIMPS) in chronic pancreatitis and pancreatic adenocarcinoma

58%
Lekstan A., Lampe P., Lewin-Kowalik J., Olakowski M., Jablonska B., Labuzek K., Jedrzejowska-Szypulka H., Olakowska E., Gorka D., Filip I., Dranka-Bojarowska D.
Journal of Physiology and Pharmacology
|
2012
|
tom 63
|
nr 6
15

Expression of epidermal growth factors and apoptosis markers in pancreatic ductal adenocarcinoma

58%
Pryczynicz A., Guzinska-Ustymowicz K., Czyzewska J., Kemona A.
Folia Histochemica et Cytobiologica
|
2009
|
tom 47
|
nr 4
16

Apoptosis in lymphocytes of pancreatic cancer patients: influence of preoperative enteral immunonutrition and extensive surgery

58%
Slotwinski R., Olszewski W., Slodkowski M., Lech G., Zaleska M., Kedziora S., Wluka A., Domaszewska A., Slotwinska S., Krasnodebski W., Wojcik Z.
Archivum Immunologiae et Therapiae Experimentalis
|
2011
|
tom 59
|
nr 5
17
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Studying the post-operatory and molecular modifications in the chronic pancreatitis and pancreatic cancer - The Importance of the micronutrients and pancreatic enzyme supplementation

58%
Timofte D., Bintintan V., Munteanu I., Blaj M., Anton E., Ciobica A., Surlin V.
International Letters of Natural Sciences
|
2015
|
tom 47
The pancreatic cancer is a disorder with an exponentially increased incidence, especially over the last few years. Moreover, it is estimated that almost 95% of the patients with this disease are presenting to the hospital in the advanced and unresectable stages. Also, over the past few decades the development and advance of the surgical methods and techniques have improved, with the most of the operatory actions in the chronic pancreatitis and pancreatic cancer being represented by the whipple duodeno-pancreatectomy, which in fact represents the standard resection for tumors of the duodenum, as well as the hepatopancreatic ampulla of Vater, distal choledocus and the head of the pancreas. Moreover, it is important to mention that in these cases, after an extended resection and reconstruction of the upper gastrointestinal tract, the digestive physiology will be disrupted. In addition, previous studies have shown that patients can maintain a body mass index after surgery but often this will be lower than its preoperative value. Thus, considering the aforementioned aspects, in the present mini-review we were mainly interested in presenting also the relevance of the micronutrients such as iron, selenium, vitamin D and E, zinc or copper in this complicated area of research, as well as aspects regarding the correlations between immune function and micronutrients or the pancreatic enzyme supplementation.
18

Badanie USG jamy brzusznej u psów i kotów - trzustka

37%
Huynh E., Berry C. R.
Weterynaria po Dyplomie
|
2019
|
tom 20
|
nr 4
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.